Correlation of LP-PLA2 and MMP-9 with the occurrence of early neurological deterioration in patients with acute ischemic stroke
Open Access
- 24 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (21) , e38310
Abstract
Early neurological deterioration is a common complication of acute ischemic stroke (AIS), which aggravates symptoms, worsens the condition, and counteracts the benefits of clinical treatment. The aim of this paper was to analyze the correlation between lipoprotein-associated phospholipase A2 (Lp-PLA2), matrix metalloproteinase-9 (MMP-9), and the occurrence of early neurological deterioration (END) in patients with AIS and to explore the clinical prediction of END by the combination of the 2 assays for the clinical prediction of END. A total of 500 AIS patients admitted to our hospital from October 2022 to October 2023 were included as study subjects, and the clinical data of all AIS patients were collected and organized to detect the levels of Lp-PLA2 and MMP-9. Categorized into END and non-END groups according to whether END occurred within 7 days of the onset of AIS, and comparing the clinical baseline data and laboratory index levels of the 2 groups. Logistic regression analysis was performed to determine the independent predictors of END, and the predictive effects of Lp-PLA2 and MMP-9 levels on END were assessed by subject work characteristics (ROC) curves. END occurred in 111 (22.2%) of 500 AIS patients. Multivariate logistic regression analysis showed that diabetes (OR 2.717, 95% CI:1.53–4.81, P < .001), baseline NIHSS score (OR 1.65, 95% CI:1.41–1.94, P < .001), Lp-PLA2 (OR 1.07, 95% CI:1.05–1.09, P < .001) and MMP-9 (OR 1.12, 95% CI:1.09–1.16, P < .001) levels were independent influences on the occurrence of END in patients with AIS after correcting for confounders. ROC curve analysis showed that Lp-PLA2, MMP-9, and a combination of both predicted END with an area under the curve was 0.730, 0.763, and 0.831, respectively, and the area under the curve for the combination of both predicting END was significantly higher than that for any of the inflammatory markers alone (P < .05). Both inflammatory markers, Lp-PLA2 and MMP-9, were independent predictors of the development of END in patients with AIS, and the combination of the two had a higher predictive value.Keywords
This publication has 27 references indexed in Scilit:
- Early Prediction of Malignant Brain Edema After Ischemic StrokeStroke, 2018
- Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patientsJournal Of Nephrology, 2018
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIANew England Journal of Medicine, 2018
- Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysisClinica Chimica Acta, 2017
- Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarctionGenetics and Molecular Research, 2015
- Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implicationsJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Matrix metalloproteinase-9 expression in carotid atherosclerotic plaque and contrast-enhanced MRI in a swine modelJournal of NeuroInterventional Surgery, 2012
- Matrix metalloproteinases as drug targets in ischemia/reperfusion injuryDrug Discovery Today, 2011
- Vascular Endothelial Growth Factor and Matrix Metalloproteinase 9 Expression in Human Carotid Atherosclerotic Plaques: Relationship with Plaque Destabilization via NeovascularizationCerebrovascular Diseases, 2004
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993